Details of the Drug Reposition

General Information of This Drug (ID: DMG65WH)

Drug Name
Ficlatuzumab   DMG65WH
Synonyms AV-299
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
4 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple myeloma DISEWP9B 2A83 Phase 2 [1]
Squamous cell carcinoma DISQVIFL 2B60-2D01 Phase 2 [2]
Pancreatic cancer DISJC981 2C10 Phase 2 [2]
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02318368) A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)